ASSENT 3Assessment of the Safety of a New Thrombolytic-3. A clinical trial comparing the efficacy and safety of tenecteplase plus enoxaparin or abciximab with tenecteplase plus weight-adjusted unfractionated heparin in patients with acute myocardial infarction (MI).
Conclusion Tenecteplase plus enoxaparin or abciximab reduced ischaemic complications of an acute MI; tenecteplase plus enoxaparin may be a reperfusion regimen warranting further study.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.